Vandetanib Active in RET-rearranged Advanced NSCLC
Vandetanib demonstrates antitumor activity among patients with advanced RET-rearranged non-small cell lung cancer (NSCLC).
ESMO 2016
Neoadjuvant CRT Improves Survival in Locally Advanced Squamous Cell Esophageal Cancer
Adding chemoradiotherapy prior to surgery improves survival versus surgery alone in patients with locally advanced esophageal squamous cell carcinoma (SCC).
Lurbinectedin Active in BRCA Mutation-positive Metastatic Breast Cancer
Lurbinectedin induces DNA double-strand breaks, and regulates the tumor microenvironment.
Biosimilar Equivalent to Pegfilgrastim for Chemo-induced Neutropenia Prophylaxis
MYL-1401H is equivalent in efficacy to pegfilgrastim for the prevention of chemotherapy-induced neutropenia among patients with breast cancer.
Ipilimumab 10 mg/kg Associated With Improved OS But More AEs in Advanced Melanoma
In contrast with a 3 mg/kg dose, ipilimumab monotherapy at a dose of 10 mg/kg is associated with improved overall survival.
Prexasertib Shows Promising Activity in High-grade Ovarian Cancer
Prexasertib demonstrates promising activity in patients with BRCA wild type sporadic high-grade serous ovarian cancer.
Selinexor May Benefit Patients Ovarian or Endometrial Cancer
Treatment with selinexor is active in patients with heavily pretreated patients with metastatic ovarian or endometrial cancer.
Metastasis-free Survival: a Surrogate for OS in Localized Prostate Cancer
Researchers can use metastasis-free survival as a surrogate end point for overall survival in clinical trials evaluating patients with localized prostate cancer.
Next post in ESMO 2016
